Hypogonadotropic hypogonadism
MONDO:0018555Abnormal ovarian or testicular function due to insufficient hormonal stimulation from the hypothalamic-pituitary axis.
Also known as: Normosmic idiopathic hypogonadotropic hypogonadism, central hypogonadism, gonadotropic deficiency, hypogonadism, hypogonadotropic, hypogonadotropic hypogonadism, hypogonadotropic hypogonadism with or without anosmia, low gonadotropins (secondary hypogonadism), nIHH
99 clinical trials for this condition and its sub-types, 19 tagged with Hypogonadotropic hypogonadism itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hypogonadotropic hypogonadism
-
Congenital hypogonadotropic hypogonadism 0 trials · 82 incl. sub-types
25 sub-types
- Combined pituitary hormone deficiencies, genetic form 1 trial · 42 incl. sub-types Sub-types →
- Prader-Willi syndrome 31 trials Sub-types →
- CHARGE syndrome 4 trials Sub-types →
- Hypogonadotropic hypogonadism 7 with or without anosmia 3 trials
- Arhinia, choanal atresia, and microphthalmia 1 trial
- Isolated congenital hypogonadotropic hypogonadism 0 trials · 1 incl. sub-types Sub-types →
- Obesity due to congenital leptin deficiency 1 trial
- Obesity due to leptin receptor gene deficiency 1 trial
- Obesity due to prohormone convertase I deficiency 1 trial
- ANE syndrome 0 trials
- Kallmann syndrome-heart disease syndrome 0 trials
- Laurence-Moon syndrome 0 trials
- Martsolf syndrome 1 0 trials
- Moebius syndrome-axonal neuropathy-hypogonadotropic hypogonadism syndrome 0 trials
- Prader-Willi-like syndrome 0 trials Sub-types →
- Woodhouse-Sakati syndrome 0 trials
- X-linked adrenal hypoplasia congenita 0 trials Sub-types →
- Ataxia-hypogonadism-choroidal dystrophy syndrome 0 trials
- Brachytelephalangy-dysmorphism-Kallmann syndrome 0 trials
- Cerebellar ataxia-hypogonadism syndrome 0 trials Sub-types →
- Familial adrenal hypoplasia with absent pituitary luteinizing hormone 0 trials
- Hypogonadotropic hypogonadism-frontoparietal alopecia syndrome 0 trials
- Hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 0 trials
- Hypogonadotropic hypogonadism-severe microcephaly-sensorineural hearing loss-dysmorphism syndrome 0 trials
- Polyendocrine-polyneuropathy syndrome 0 trials
-
Kallmann syndrome 3 trials
18 sub-types
- Hypogonadotropic hypogonadism 1 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 11 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 14 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 15 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 16 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 17 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 18 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 19 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 2 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 20 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 21 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 22 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 3 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 4 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 5 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 6 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 8 with or without anosmia 0 trials
- Hypogonadotropic hypogonadism 9 with or without anosmia 0 trials
Most studied deeper sub-types
-
New nasal spray aims to curb relentless hunger in rare genetic disorder
Disease control Stopped earlyThis study tests the long-term safety of a nasal spray called carbetocin for people with Prader-Willi syndrome who experience severe, constant hunger (hyperphagia). About 160 participants who completed a previous study will receive the spray three times daily. The goal is to see …
Phase 3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for rare hunger disorder: drug shows promise in Long-Term trial
Disease control Stopped earlyThis study tests whether ARD-101 can safely reduce extreme hunger and food-related behaviors in people with Prader-Willi syndrome over 12 months. About 90 participants who completed a prior study will take the drug daily and visit the clinic regularly. The goal is to improve qual…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a daily injection reshape bodies of HIV patients?
Disease control Stopped earlyThis study looked at whether tesamorelin (Egrifta), a daily injection that boosts growth hormone, can improve body composition in people with HIV who have excess belly fat (lipodystrophy). Six participants received the drug for up to 12 months, with researchers measuring liver fa…
Phase 4 • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New oral test could replace painful insulin injections for hormone diagnosis
Diagnosis Stopped earlyThis study tested a new oral drink (GS3-007a) to diagnose adult growth hormone deficiency (AGHD). It compared the drink to the standard insulin tolerance test in 120 adults suspected of having AGHD and healthy volunteers. The goal was to see if the oral test works as well as the …
Phase 2 • Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
Hope for rare hunger disorder: new drug enters final testing phase
Symptom relief Stopped earlyThis phase 3 trial tests whether ARD-101 can reduce the intense, constant hunger (hyperphagia) seen in Prader-Willi syndrome. About 90 participants will take either ARD-101 or a placebo daily for 12 weeks. Caregivers will track changes in hunger-related behaviors using a standard…
Phase 3 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
CBDV study for Prader-Willi syndrome halted early
Symptom relief Stopped earlyThis study tested whether a cannabis-derived compound called CBDV could safely reduce irritability in children and young adults with Prader-Willi syndrome. Only 6 people enrolled before the study was stopped early. The goal was to see if CBDV helped with mood and behavior problem…
Phase 2 • Sponsor: Eric Hollander • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Brain and eye clues to emotion recognition in autism and psychosis
Knowledge-focused Stopped earlyThis study aimed to understand why people with autism or schizophrenia sometimes struggle to recognize emotions on faces. Researchers used brain wave recordings (EEG) and eye-tracking to see how participants processed facial expressions. The study included people with autism, sch…
Sponsor: Hôpital le Vinatier • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC